Landi D. Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS. Abstract 338. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.
ECTRIMS 2015 video update Zwanikken: Innovative therapeutic strategies
jun 2017